Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 9:30 pm Purchase | 2024-12-31 | 13G | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 171,000 4.920% | 130,968 (+327.16%) | Filing History |
| 2024-01-19 10:31 am Purchase | 2023-12-31 | 13G | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 40,032 9.990% | 2,871 (+7.73%) | Filing History |
| 2023-09-08 06:07 am Unchanged | 2023-07-06 | 13G | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 37,161 9.900% | 0 (Unchanged) | Filing History |
| 2023-08-24 08:20 am Purchase | 2022-05-19 | 13G | COMERA LIFE SCIENCE HLDGS INC CMRA | Nicholas Jason Singer | 1,445,448 5.170% | 1,445,448 (New Position) | Filing History |
| 2023-07-26 5:05 pm Purchase | 2023-04-03 | 13D | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 37,161 9.990% | 10,910 (+41.56%) | Filing History |
| 2022-12-20 4:30 pm Sale | 2022-12-02 | 13D | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Nicholas Jason Singer | 393,766 7.670% | -1,701,234 (-81.20%) | Filing History |
| 2022-02-16 5:15 pm Sale | 2021-12-31 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Nicholas Jason Singer | 2,095,000 4.000% | -1,696,983 (-44.75%) | Filing History |
| 2021-04-30 4:05 pm Purchase | 2021-03-25 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Nicholas Jason Singer | 3,791,983 9.130% | 3,791,983 (New Position) | Filing History |